1319 ET - Bicycle Therapeutics takes a beating after sharing its latest cancer treatment trial results. B. Riley analyst Kalpit Patel says the results for Bicycle's zelenectide pevedotin therapy in conjunction with Merck's pembrolizumab to treat bladder cancer included "a significant proportion of unconfirmed responses," and while the data are early, he says the effectiveness appears to be "somewhat underwhelming," when compared to the established combination of Astellas' Padcev + pembro. Patel also says results for Bicycle's breast and lung cancer treatment relied on a post-hoc analysis, which carries "an inherent risk of data mining." The analyst cautions that outcomes from such analyses often fail to replicate in later studies. Bicycle Therapeutics plunges 30% to $14.07. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
December 13, 2024 13:19 ET (18:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。